576 related articles for article (PubMed ID: 24316030)
1. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
[TBL] [Abstract][Full Text] [Related]
3. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
4. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population.
Wang H; Wu H; Bao S; Xiang X; Zhao G; Liu K; Li F; Xu Y; An B; Zhou H; Lu J; Xie Q
Infect Genet Evol; 2015 Apr; 31():161-8. PubMed ID: 25640825
[TBL] [Abstract][Full Text] [Related]
5. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
6. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
Lampertico P; Viganò M; Cheroni C; Facchetti F; Invernizzi F; Valveri V; Soffredini R; Abrignani S; De Francesco R; Colombo M
Hepatology; 2013 Mar; 57(3):890-6. PubMed ID: 22473858
[TBL] [Abstract][Full Text] [Related]
7. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
[TBL] [Abstract][Full Text] [Related]
8. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
Wei L; Wedemeyer H; Liaw YF; Chan HL; Piratvisuth T; Marcellin P; Jia J; Tan D; Chow WC; Brunetto MR; Diago M; Gurel S; Morozov V; He H; Zhu Y; Wat C; Surujbally B; Thompson AJ
PLoS One; 2018; 13(7):e0199198. PubMed ID: 30016335
[TBL] [Abstract][Full Text] [Related]
9. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
[TBL] [Abstract][Full Text] [Related]
10. Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B.
Limothai U; Chuaypen N; Khlaiphuengsin A; Chittmittraprap S; Poovorawan Y; Tangkijvanich P
Antivir Ther; 2017; 22(8):681-688. PubMed ID: 28291736
[TBL] [Abstract][Full Text] [Related]
11. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
Boglione L; Cariti G; Di Perri G; D'Avolio A
J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
[TBL] [Abstract][Full Text] [Related]
12. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
13. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon.
Boglione L; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2015 Mar; 22(3):318-27. PubMed ID: 25060765
[TBL] [Abstract][Full Text] [Related]
14. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
15. Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B.
Limothai U; Wasitthankasem R; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2015; 16(13):5515-9. PubMed ID: 26225703
[TBL] [Abstract][Full Text] [Related]
16. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
17. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
18. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
[TBL] [Abstract][Full Text] [Related]
19. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B.
Wu H; Zhao G; Qian F; Liu K; Xie J; Zhou H; Xu J; Xu Y; Han Y; Xie Q; Wang H
Liver Int; 2015 Feb; 35(2):473-81. PubMed ID: 24517415
[TBL] [Abstract][Full Text] [Related]
20. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study.
Lee IC; Huang YH; Su CW; Wang YJ; Huo TI; Lee KC; Lin HC
PLoS One; 2013; 8(10):e76798. PubMed ID: 24124595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
